UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of January, 2020
 
Commission File Number 001-15170
 
 
GlaxoSmithKline plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
 
 
 
GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Ms E Walmsley
b)
Position/status
 
Chief Executive Officer
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£17.9020
195
 
 
£17.9020
195
 
 
£17.9020
684
 
 
£17.9020
680
 
 
 
 
 
d)
Aggregated information
 
1,754
Aggregated volume
Price
 
£17.9020
e)
Date of the transaction
 
2020-01-13
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R Connor     
 
b)
Position/status
 
President, Global Vaccines
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
 
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£17.9020
101
 
 
£17.9020
101
 
 
£17.9020
144
 
 
£17.9020
178
 
 
 
 
 
d)
Aggregated information
 
524
Aggregated volume
Price
 
£17.9020
e)
Date of the transaction
 
2020-01-13
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Mr N Hirons
b)
Position/status
 
SVP, Global Ethics & Compliance
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
 
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£17.9020
64
 
 
£17.9020
64
 
 
£17.9020
75
 
 
£17.9020
74
 
 
 
 
 
d)
Aggregated information
 
277
Aggregated volume
Price
 
£17.9020
e)
Date of the transaction
 
2020-01-13
f)
Place of the transaction
 
London Stock Exchange (XLON)
 

 
  
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Mr L Miels
b)
Position/status
 
President, Global Pharmaceuticals
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
 
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£17.9020
137
 
 
£17.9020
190
 
 
 
 
 
d)
Aggregated information
 
327
Aggregated volume
Price
 
£17.9020
e)
Date of the transaction
 
2020-01-13
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Mr D Redfern
b)
Position/status
 
Chief Strategy Officer
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
 
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£17.9020
80
 
 
£17.9020
80
 
 
£17.9020
140
 
 
£17.9020
168
 
 
 
 
 
d)
Aggregated information
 
468
Aggregated volume
Price
 
£17.9020
e)
Date of the transaction
 
2020-01-13
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Mr R Simard
b)
Position/status
 
President, Pharmaceuticals Supply Chain
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
 
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£17.9020
61
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2020-01-13
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Mr P Thomson
b)
Position/status
 
President, Global Affairs
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
 
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£17.9020
76
 
 
£17.9020
95
 
 
£17.9020
98
 
 
 
 
 
d)
Aggregated information
 
269
Aggregated volume
Price
 
£17.9020
e)
Date of the transaction
 
2020-01-13
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Mr B McNamara
b)
Position/status
 
CEO, GSK Consumer Healthcare
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
b)
Nature of the transaction
 
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 January 2020 on ADSs held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
$46.6500
74
 
 
$46.6500
72
 
 
$46.6500
68
 
 
 
 
 
 
 
 
 
d)
Aggregated information
 
214
Aggregated volume
Price
 
$46.6500
e)
Date of the transaction
 
2020-01-13
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Dr H Barron
b)
Position/status
 
Chief Scientific Officer and President, R&D
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
b)
Nature of the transaction
 
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 January 2020 on ADSs held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
$46.6500
406
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2020-01-13
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
      
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Mr J Ford
b)
Position/status
 
Senior Vice President and General Counsel
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
b)
Nature of the transaction
 
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 January 2020 on ADSs held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
$46.6500
35
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2020-01-13
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Ms K Terrell
b)
Position/status
 
Chief Digital & Technology Officer
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
b)
Nature of the transaction
 
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 January 2020 on ADSs held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
$46.6500
24
 
 
$46.6500
86
 
 
 
 
 
d)
Aggregated information
 
110
Aggregated volume
Price
 
$46.6500
e)
Date of the transaction
 
2020-01-13
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: January 15, 2020 
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc